Japanese drugmaker Ayumi Pharmaceutical Corp. has entered into a contract to be acquired by U.S.-based private equity firm Blackstone Group.
Blackstone Group is expecting to pay about $1 billion for Ayumi Pharmaceutical, including the debt.
As part of the deal, Blackstone will buy Ayumi’s anti-rheumatism drugs from investment firm Unison Capital and medical information site business M3.
With the acquisition, Blackstone will leverage its global footprint and expertise in this sector to help Ayumi meet the growing need for its rheumatoid arthritis and orthopaedic products.